Corcept Therapeutics beats Q3 estimates but shares fall on guidance
CORT Corcept Therapeutics Inc
$74.53 +1.61%
View chart & analysis → - 1Corcept Therapeutics Incorporated reported adjusted earnings per share of $1.01 for the third quarter.
- 2Third quarter revenue was $340.5 million, a 64% increase compared to the same period last year.
- 3Corcept Therapeutics shares fell 3.9% in Tuesday after-hours trading.
So what's the key point?
Corcept Therapeutics' third quarter results were better than what experts expected. However, the stock price fell 3.9%.
Source Investing.com +2 · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.